Zhong Huijuan
- Net worth $18.5 billion
- Status -
- Country China
- Source(-s) of wealth Businesswoman, Entrepreneur
How much is Zhong Huijuan Worth? Zhong Huijuan Net Worth in 2026
Zhong Huijuan’s net worth is estimated at $18.5 billion as of November 2026. In October Roche signed a cancer drug deal with her company that made headlines at more than $15 billion. The money Roche has firmly committed is $510 million, and her share of that, through her 64% stake, works out to about $328 million.
| Net worth | $18.5 billion (our estimate) |
|---|---|
| Born | 1961 (age 64 or 65) |
| Country | China |
| Known for | Founder and chair of Hansoh Pharmaceutical |
| Main income sources | Hansoh shares held through a family trust structure, Hengrui stake, dividends |
How much is Zhong Huijuan worth in 2026?
About $18.5 billion, by our estimate. Nearly all of it is one block of 3.9 billion Hansoh shares, 64.41% of the company, priced at HK$35.02 at the November 10, 2026 close in Hong Kong. We add a reported 2% stake in Jiangsu Hengrui, the drugmaker her husband Sun Piaoyang ran for decades, and the interim dividend Hansoh declared in August. Conversions use HK$7.845 and 6.671 yuan per dollar, the mid-market rates on November 10.
Building the $18.5 billion
| Source | Our estimate | What it rests on |
|---|---|---|
| Hansoh, 3.9 billion shares | $17.41 billion | The full block at HK$35.02, about HK$136.6 billion. |
| Jiangsu Hengrui, about 2% | $959 million | 2% of Hengrui’s market value of 319.79 billion yuan on November 10, 2026. The 2% is from a December 2025 VnExpress report; we have not seen a filing. |
| 2026 interim dividend | $142 million | HK 28.5 cents a share on that block, about HK$1.11 billion, declared in August 2026. |
| Total | $18.5 billion | $18,510 million before rounding. |
One block, two names
Hong Kong disclosure filings list the same 3.9 billion Hansoh shares under several names: Zhong, a company called Stellar Infinity, two trust-related entities, and her daughter, Sun Yuan, according to the etnet disclosure log of filings dated August 27, 2025. Sun Yuan, an executive director who oversees research, appears again in 2026 filings at about 64.36%. In other words, the controlling stake sits in a family trust structure, not in one person’s brokerage account. We credit the block to Zhong because she founded the company and chairs it, but a reader could fairly split it with her daughter.
The Roche money, scaled to her
Roche agreed on October 19, 2026 to pay Hansoh $400 million upfront and $110 million on the first anniversary, with more than $15 billion of possible milestones and tiered royalties on top, Pharmaceutical Executive reported. Hansoh keeps the rights in mainland China, Hong Kong, Macau and Taiwan. Our calculation: the firm $510 million is the part that exists today, and 64.41% of it is about $328 million. That is 1.8% of her fortune. The other $15 billion depends on drug programs, two of which are still preclinical.
Hansoh’s ordinary business moves her more. In the first half of 2026 it reported revenue of 8.304 billion yuan, up 11.71%, and profit attributable to shareholders of 4.258 billion yuan, up 35.82%, according to its interim results. Her 64.41% of that half-year profit is about 2.74 billion yuan, or $411 million, by our calculation.
From the chemistry classroom
Zhong was born in 1961, earned a chemistry degree from Jiangsu Normal University at 21 and taught chemistry at a middle school in Lianyungang, VnExpress reported. She left teaching in 1995 to start Jiangsu Hansoh Pharmaceutical with about 10 employees. Revenue was $4.5 million in 1997. The company listed in Hong Kong in 2019, raising $1 billion. Her husband, Sun Piaoyang, built a career at the state drug factory in Lianyungang that became Jiangsu Hengrui, which he chaired for decades. It is a separate company.
Why other estimates disagree
Some public estimates fold in the couple’s combined holdings, including Sun Piaoyang’s own Hengrui fortune, which is his. Others leave out her reported Hengrui stake or the dividend, and a few split the trust block with her daughter. Timing matters too, since the figure rests on a share price that moves every trading day.
What would move the figure
Each HK$1 on Hansoh’s share price changes our figure by about $497 million, by our calculation. The next firm cash from Roche is the $110 million due in October 2027. A filing that confirms or corrects the Hengrui stake would firm up our second row.
Zhong Huijuan net worth FAQ
What is Zhong Huijuan’s net worth?
About $18.5 billion as of November 2026 by our estimate, almost all from her controlling Hansoh stake at the November 10 price.
How much of Hansoh does Zhong Huijuan own?
Filings list 3.9 billion shares, 64.41%, held through a family trust structure in which her daughter Sun Yuan is also named.
How much did Zhong Huijuan make from the Roche deal?
Nothing directly; Roche pays Hansoh. Her 64.41% share of the firm $510 million is about $328 million by our calculation.
How much profit did Hansoh make in 2026?
4.258 billion yuan attributable to shareholders in the first half of 2026, up 35.82%, on revenue of 8.304 billion yuan.
How old is Zhong Huijuan?
She was born in 1961, so she is 64 or 65.
Who is Zhong Huijuan’s husband?
Sun Piaoyang, who led Jiangsu Hengrui for decades. Hengrui and Hansoh are separate companies.
Related profiles
- Jensen Huang net worth
- MacKenzie Scott net worth
- Abigail Johnson net worth
- Oprah Winfrey net worth
- Bill Gates net worth
How we estimate net worth
Our estimates are based on public reporting, company valuations, and deal and earnings figures all compiled in an internal valuation model. They are approximate, and figures change over time as new information emerges.
Last updated: November 2026.